Parathyroid tumors and related disorders

Modern Pathology

Volumn 24, Issue , 2011, Pages S78-S93

  Delellis, Ronald A ^a,b  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

99mTc sestamibi; Carcinoma; HPT JT syndrome; MEN 1; Molecular diagnostics; Parafibromin; Parathyromatosis

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PARATHYROID HORMONE;

ARTICLE; ATYPICAL ADENOMA; CELL HYPERPLASIA; CHIEF CELL HYPERPLASIA; DISEASE CLASSIFICATION; ENDOCRINE DISEASE; FAMILIAL HYPERCALCEMIC HYPERCALCURIA; FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; FAMILIAL ISOLATED HYPERPARATHYROIDISM; HORMONE DETERMINATION; HUMAN; HYPERPARATHYROIDISM; HYPERPARATHYROIDISM JAW TUMOR SYNDROME; INTRAOPERATIVE PERIOD; MULTIPLE ENDOCRINE NEOPLASIA 1; MULTIPLE ENDOCRINE NEOPLASIA 2A; NEONATAL SEVERE PRIMARY HYPERPARATHYROIDISM; PARATHYROID ADENOMA; PARATHYROID CARCINOMA; PARATHYROID CELL; PARATHYROID DISEASE; PARATHYROID TUMOR; PARATHYROIDECTOMY; PARATHYROMATOSIS; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TERTIARY HYPERPARATHYROIDISM; TUMOR CELL; TUMOR LOCALIZATION; ULTRASOUND; WATER CLEAR CELL HYPERPLASIA;

ADENOMA; HUMANS; HYPERPARATHYROIDISM, PRIMARY; HYPERPLASIA; INTRAOPERATIVE PERIOD; JAW NEOPLASMS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; PARATHYROID GLANDS; PARATHYROID HORMONE; PARATHYROID NEOPLASMS; SYNDROME;

EID: 79953299507     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.132     Document Type: Article

References (86)

1. Zink AR, Panzer S, Fesq-Martin M, et al. Evidence for a 7000-year old case of primary hyperparathyroidism. JAMA 2005;293:40-42.
2. Carney AJ. The glandulae parathyroideae of Ivar Sandstro¨m: contributions from two continents. Am J Surg Pathol 1996;20:1123-1144.
3. Organ CH. The history of parathyroid surgery 1850-1996: the excelsior surgical society 1998, Edward G. Churchill lecture. J Am Coll Surg 2000;191:284-299.
4. Melton LJ. The epidemiology of primary hyperparathyroidism in North America. J Bone Miner Res 2002; 17(Suppl 2):N12-N17.
5. Fraser WD. Hyperparathyroidism. Lancet 2009;374: 145-158.
6. Wermers RA, Khosia S, Atkinson EJ, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on changing epidemiology of the disease. J Bone Miner Res 2006;21:171-177.
7. Monchik JM. Normocalcemic hyperparathyroidism. Surgery 1995;118:917-923.
8. DeLellis RA, Mazzaglia P, Mangray S. Primary hyperparathyroidism: a current perspective. Arch Pathol Lab Med 2008;132:1251-1262.
9. Molinari AS, Irvin III GL, Deriso GT, et al. Incidence of multiglandular disease in primary hyperparathyroidism determined by parathyroid hormone secretion. Surgery 1996;120:934-936.
10. Van Houten JN, Yu N, Rimm D, et al. Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene. J Clin Endocrinol Metab 2006;91:580-583.
11. Lumachi F, Brunello A, Roma A, et al. Cancer induced hypercalcemia. Anti Cancer Res 2009;29:1551-1555.
12. DeLellis RA. Tumors of the Parathyroid Gland. Atlas of Tumor Pathology, 3rd series, fascicle6 Armed Forces Institute of Pathology: Washington, DC, 1993.
13. Grimelius L, DeLellis RA, Bondeson L, et al. Parathyroid adenoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds). Pathology and Genetics of Tumours of Endocrine Organs. World Health Organization Classification of Tumours, IARC Press: Lyon, France, 2004, pp 128-132.
14. Verdonk CA, Edis AJ. Parathyroid ‘double adenomas’: fact or fiction? Surgery 1981;80:523-526.
15. Milas M, Wagner K, Easley KA, et al. Double adenomas revisited: nonuniform distribution favors enlarged superior parathyroids (fourth pouch disease). Surgery 2003;134:995-1003.
16. Snover D, Foucar K. Mitotic activity in benign parathyroid disease. Am J Clin Pathol 1981;75:345-347.
17. Abbona CG, Papotti M, Gasparri G, et al. Proliferative activity in parathyroid tumors as detected by Ki-67 immunostaining. Hum Pathol 1995;26:135-138.
18. Vargas MP, Vargas HI, Keiner DE, et al. The role of prognostic markers (MIB-1, RB and bcl-2) in the diagnosis of parathyroid tumors. Mod Pathol 1997;10:12-17.
19. Erickson LA, Jin L, Wollan P, et al. Parathyroid hyperplasia, adenomas and carcinomas: differential expression of p27 Kip1 protein. Am J Surg Pathol 1999; 23:288-295.
20. Isotalo PA, Lloyd RV. Presence of birefringent crystals in useful in distinguishing thyroid from parathyroid gland tissues. Am J Surg Pathol 1999; 23:288-295.
21. Arnold A, Shattuck TM, Mallya SM, et al. Molecular pathogenesis of primary hyperparathyroidism. J Bone Miner Res 2002;17:N30-N36.
22. Westin G, Björklund P, Akerström G. Molecular genetics of parathyroid disease. World J Surg 2009;33: 2224-2233.
23. Chandrasekharappa SC, Guru SC, Manickham P, et al. Positional cloning of the gene for multiple endocrine neoplasia type1. Science 1997;276:404-407.
24. Lemmens I, Van deVen WJ, Kas K, et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum Mol Genet 1997;6:1177-1183.
25. Imanishi Y. Molecular pathogenesis of tumorigenesis in sporadic parathyroid adenomas. J Bone Miner Metab 2002;20:190-195.
26. Palanisamy N, Imanishi Y, Rao PH, et al. Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas. J Clin Endocrinol Metab 1998;83:1766-1770.
27. Greene AB, Butler RS, McIntyre S, et al. National trends in parathyroid surgery from 1998 to 2008: a decade of change. J Am Coll Surg 2009;209:332-343.
28. Johnson NA, Tublin ME, Ogilve JB. Parathyroid imaging: technique and role in the preoperative evaluation of primary hyperparathyroidism. Am J Roentgenol 2007;188:1706-1715.
29. Taillefer R, Boucher Y, Potvin C, et al. Detection and localization of parathyroid adenomas in patients with hypoparathyroidism using a single radionuclide imaging procedure with technetiuym-99m-sestamibi (double phase study). J Nucl Med 1992;33:1801-1807.
30. Irvin III GL, Dembrow VD, Prudhomme DL. Operative monitoring of parathyroid gland hyperfunction. Am J Surg 1991;162:299-302.
31. Udelsman R. Six hundred fifty-six consecutive explorations for primary hyperparathyroidism. Ann Surg 2002;235:665-670.
32. Carneiro DM, Solorzano CC, Irvin III GL. Recurrent disease after limited parathyroidectomy for sporadic primary hyperparathyroidism. J Am Coll Surg 2004; 199:849-853.
33. Garner SC, Leight Jr GS. Initial experience with intraoperative PTH determinations in the surgical management of 130 consecutive cases of primary hyperparathyroidism. Surgery 1999;126:1132-1137.
34. Vignali E, Picone A, Materazzi G, et al. A quick intraoperative parathyroid hormone assay in the surgical management of patients with primary hyperparathyroidism: a study of 206 consecutive cases. Eur J Endocrinol 2002;146:783-788.
35. Biskobing DM. Significance of elevated PTH after parathyroidectomy. Endocrine Pract 2009;16:112-117.
36. Marcocci C, Cetani F, Rubin MR, et al. Review: parathyroid carcinoma. J Bone Miner Res 2008;23: 1869-1880.
37. DeLellis RA. Parathyroid carcinoma. Adv Anat Pathol 2004;12:53-61.
38. Boyle NH, Ogg CS, Hartley RB, et al. Parathyroid carcinoma secondary to prolonged hyperplasia in chronic renal failure and celiac disease. Eur J Surg Oncol 1999;25:100-103.
39. Chen JD, Morrison C, Zhang C, et al. Hyperparathyroidism— jaw tumor syndrome. J Int Med 2003;253: 634-642.
40. Wassif WS, Moniz CF, Friedman E, et al. Familial isolated hyperparathyroidism: a distinct genetic entity with an increased risk of parathyroid cancer. J Clin Endocrinol Metab 1993;77:1485-1489.
41. Agah A, Carpenter R, Bhattacharya S, et al. Parathyroid carcinoma in multiple endocrine neoplasia type 1 (MEN1) syndrome: two case reports of an unrecognized entity. J Endocrinol Invest 2007;30:145-149.
42. Jenkins PJ, Satta MA, Simmgen M, et al. Metastatic parathyroid carcinoma in MEN2A syndrome. Clin Endocrinol (Oxf) 1997;47:747-751.
43. Wilkins BJ, Lewis JS. Non-functional parathyroid carcinoma: a review of the literature and report of a case requiring extensive surgery. Head Neck Pathol 2009;3:140-149.
44. Sandelin K, Tullgen D, Farnebo O. Clinical course of parathyroid cancer. World J Surg 1994;18:594-598.
45. Ippolito G, Plazzo FF, Sebag F, et al. Intraoperative diagnosis and treatment of parathyroid cancer and atypical parathyroid adenoma. Br J Surg 2007;94: 566-570.
46. Schantz A, Castleman B. Parathyroid carcinoma. A study of 70 cases. Cancer 1973;31:600-605.
47. Bondeson L, Grimelius L, DeLellis RA, et al. Parathyroid carcinoma. In: DeLellis RA, Lloyd RV, Heitz PU and Eng C (eds). Pathology and Genetics of Tumours of Endocrine Organs. WHO classification of Endocrine Tumours, IARC Press: Lyon, 2004. pp 124-127.
48. Bondeson L, Sandelin K, Grimelius L. Histopathological variables and DNA cytometry in parathyroid carcinomas. Am J Surg Pathol 1993;17:820-829.
49. Hundahl SA, Fleming ID, Fremgen AM, et al. Two hundred eighty-six cases of parathyroid carcinoma treated in the US between 1985-1995. A national cancer data base report. Cancer 1999;86:538-544.
50. Cryns VK, Thor A, Xu HJ. Loss of the retinoblastoma tumor suppressor gene in parathyroid carcinoma. N Eng J Med 1994;330:757-761.
51. Lloyd RV, Carney JA, Ferreiro JA, et al. Immunohistochemical analysis of the cell cycle associated antigens Ki-67 and retinoblastoma protein in parathyroid carcinomas and adenomas. Endocr Pathol 1995;6: 279-287.
52. Cetani F, Pardi E, Vlacava P, et al. A reappraisal of the Rb-1 gene abnormalities in the diagnosis of parathyroid carcinoma. Clin Endocrinol 2004;60:99-106.
53. Shattuck TM, Kim TS, Costa J, et al. Mutational analysis of RB and BRCA2 as candidate tumor suppressor genes in parathyroid carcinomas. Clin Endocrinol 2003;59:180-189.
54. Teh BT, Sweet KM, Morrison CD. Hyperparathyroidism-jaw tumour syndrome. In: DeLellis RA, Lloyd RV, Heitz PU and Eng C (eds). Pathology and Genetics of Tumours of Endocrine Organs. WHO Classification of Endocrine Tumours, IARC Press: Lyon, 2004. pp 228-229.
55. Carpten JD, Robbins CM, Villablanca A, et al. HRPT2 encoding parafibromin is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 2002;32: 676-680.
56. Howell VM, Haven CJ, Kahnoski K, et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumors. J Med Genet 2003;40:657-663.
57. Shattuck TM, Valimaki S, Obara T, et al. Somatic and germline mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 2003;349: 1722-1729.
58. Tan MH, Morrison C, Wang P, et al. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res 2004;10: 6629-6637.
59. Gill AJ, Clarkson A, Gimm O. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinoma and hyperparathyroidism-jaw tumor associated adenoma from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol 2006;30: 1140-1149.
60. Juhlin CC, Villablanca A, Sandelin K, et al. Parafibromin immunoreactivity; its use as an additional diagnostic marker for parathyroid tumor classification. Endocrin Relat Cancer 2007;14:501-512.
61. Mangray S, DeLellis RA. Parafibromin as a tool for the diagnosis of parathyroid tumors (letter). Adv Anat Pathol 2008;15:179.
62. Tominaga Y, Tsuzuki T, Matsuoka A, et al. Expression of parafibromin in distant metastatic parathyroid tumors in patients with advanced secondary hyperparathyroidism due to chronic kidney disease. World J Surg 2008;32:815-821.
63. Cetani F, Ambrogini E, Viacava P, et al. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol 2007;156: 547-554.
64. Bergero N, DePompa R, Sacerdote C, et al. Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Hum Pathol 2005;36: 908-914.
65. Howell VM, Gill A, Clarkson A, et al. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab 2009;94:343-441.
66. Juhlin CC, Haglund F, Villablanca A, et al. Loss of expression for the Wnt pathway components adenomatous polyposis coli and glycogen synthase kinase 3B in parathyroid carcinomas. Int J Oncol 2009;34: 481-492.
67. Levin KE, Chew KL, Ljung BM, et al. Deoxyribonucleic acid cytometry helps identify parathyroid carcinomas. J Clin Endocrinol Metab 1988;67:779-784.
68. Guiter GE, DeLellis RA. Risk of recurrence or metastasis in atypical parathyroid adenomas. Mod Pathol 2002;15:115A.
69. Fernandez-Ranvier GG, Khanafshar E, Jensen K, et al. Parathyroid carcinoma, atypical parathyroid adenomas, or parathyromatosis? Cancer 2007;110:255-264.
70. Stojadinovic A, Hoos A, Nissar A, et al. Parathyroid neoplasms: clinical, histopathologic and tissue microarray-based molecular analysis. Hum Pathol 2003;34:54-64.
71. Fernandez-Ranvier GG, Khanafshar E, Tacha D, et al. Defining a molecular phenotype for benign and malignant parathyroid tumours. Cancer 2009;115: 334-344.
72. DeLellis RA. Tumors of the Parathyroid Gland. Atlas of Tumor Pathology. Armed Forces Institute of Pathology: Washington, DC, 1978.
73. Cope O, Keynes WM, Roth SI, et al. Primary chief cell hyperplasia of the parathyroid glands. A new entity in the surgery of hyperparathyroidism. Ann Surg 1958;148:275-388.
74. Marx SJ, Simonds WF, Agarwal SK, et al. Hereditary hyperparathyroidism in hereditary syndromes: special expressions and special management. J Bone Miner Res 2002;17(Suppl 2):N37-N43.
75. Calender A, Morrison CS, Kommioth P, et al. Multiple endocrine neoplasia type1. In: DeLellis RA, Lloyd RV, Heitz PU and Eng C (eds). Pathology and Genetics of Tumours of Endocrine Organs. WHO Classification of Endocrine Tumours, IARC Press: Lyon, 2004, pp 218-227.
76. Gimm O, Morrison CD, Suster S, et al. Multiple endocrine neoplasia type2. In: DeLellis RA, Lloyd RV, Heitz PU and Eng C (eds). Pathology of Genetics of Tumours of Endocrine Organs. WHO Classification of Endocrine Tumours, IARC Press: Lyon, 2004, pp 211-217.
77. Simonds WF, James-Newton O, Agarwal AK, et al. Familial isolated hyperparathyroidism: clinical and genetic characterizations of 36 kindreds. Medicine 2002;81:1-26.
78. Carling T, Szabo E, Bai M, et al. Familial hypercalcemia and hypercalcuric caused by a novel mutation in the cytoplasmic tail of the calcium receptor. J Clin Endocrinol Metab 2000;85:2042-2047.
79. Friedman E, Sakaguchi K, Bale AE, et al. Clonality of parathyroid tumors in familial multiple endocrine neoplasia type1. N Engl J Med 1989;321:213-218.
80. Thakker RV, Bouloux P, Wooding K, et al. Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome11. N Engl J Med 1989;321:218-224.
81. Arnold A, Brown MF, Urena P, et al. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 1995;95: 2047-2053.
82. Albright F, Bloomberg E, Castleman B, et al. Hyperparathyroidism due to diffuse hyperplasia of all parathyroid glands rather than adenoma of one. Clinical Studies on three such cases. Arch Int Med 1934;54:35-329.
83. Roth SI. The ultrastructure of primary water-clear cell hyperplasia of the parathyroid glands. Am J Pathol 1970;61:233-248.
84. Kuhel WI, Gonzales D, Hoda SA, et al. Synchronous water clear cell double parathyroid adenomas: a hitherto uncharacterized entity. Arch Pathol Lab Med 2001;125:256-259.
85. Reddick RL, Costa JC, Marx SJ. Parathyroid hyperplasia and parathyromatosis. Lancet 1977;1:549.
86. Rattner DW, Marrone GC, Kasdon E, et al. Recurrent hyperparathyroidism due to implantation of parathyroid tissue. Am Surg 1985;149:745-748.